Heparin-induced skin lesions: More common than suspected

Phlebologie

Volumn 39, Issue 1, 2010, Pages 5-11

  Schindewolf, M ^a   Kahle, B ^b   Lindhoff Last, E ^a   Ludwig, Ralf J ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Allergy; Delayed type hypersensitivity; Heparin; Skin

Indexed keywords

ANTIHISTAMINIC AGENT; ARGATROBAN; CERTOPARIN; CHONDROITIN SULFATE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CORTICOSTEROID; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; THROMBOCYTE FACTOR 4; TINZAPARIN;

ALLERGY TEST; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTICOAGULANT THERAPY; ARTERY EMBOLISM; ARTERY THROMBOSIS; BRONCHOSPASM; BULLOUS SKIN DISEASE; CLINICAL FEATURE; COMPLEMENT ACTIVATION; DELAYED HYPERSENSITIVITY; DIAGNOSTIC TEST; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; ENZYME IMMUNOASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HISTOPATHOLOGY; HUMAN; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOPATHOGENESIS; INJECTION SITE URTICARIA; MOLECULAR WEIGHT; PROVOCATION TEST; PUSTULOSIS; REVIEW; RHINOCONJUNCTIVITIS; SKIN BIOPSY; SKIN DEFECT; SKIN MANIFESTATION; SKIN NECROSIS; THROMBOCYTE COUNT; URTICARIA; VENOUS THROMBOEMBOLISM; WOUND CARE;

EID: 77149167808     PISSN: 0939978X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1622289     Document Type: Review

References (73)

1. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 1212-1220.
2. Ahmed T, Garrigo J, Danta I. Preventing broncho-constriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993; 329: 90-95.
3. Alban S. Carbohydrates with anticoagulant and antithrombotic properties. In: Witczak ZJ, Nieforth KA (eds). Carbohydrates in drug design. New York: Marcel Dekker 1997, 209-276.
4. Alban S. From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest 2005; 35: 12-20.
5. Alban S, Ludwig RJ, Bendas G, Schön MP, Oostingh GJ, Radeke HH, Fritzsche J, Pfeilschifter J, Kaufmann R, Boehncke WH. PS3, A semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. J Invest Dermatol 2009; 129: 1192-1202.
6. Anderson CL, Chacko GW, Osborne JM, Brandt JT. The Fc receptor for immunoglobulin G (Fc gamma RII) on human platelets. Semin Thromb Hemost 1995; 21: 1-9.
7. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GE. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin 3 and by gel filtration. Thromb Res 1976; 9: 575-583.
8. Bank I, Libourel EJ, Middeldorp S, Van Der MJ, Buller HR. High rate of skin complications due to low-molecular-weight heparins in pregnant women. J Thromb Haemost 2003; 1: 859-861.
9. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-1310.
10. Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert JM, van Boeckel CA, Meuleman DG. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002; 20: 37-52.
11. Beltraminelli H, Itin P, Cerroni L. Intraepidermal bullous haemorrhage during anticoagulation with low-molecular-weight heparin: two cases. Br J Dermatol 2009; 161: 191-193.
12. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 2006; 61: 1432-1440.
13. Björg I, Olson ST, Shore JD. Molecular mechanisms of the accelerating effect on the reactions between antithrombin and clotting proteases. In: Lane DA, Lindahl U (eds). Heparin, chemical and biological properties, clinical applications. Boca Raton, Fl: CRC Press 1989; 229-256.
14. Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F. Cardiovascular collapse and refractory bronchospasm following administration of vanco-mycin, esmolol, and heparin. J Cardiothorac Anesth 1989; 3: 748-751.
15. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98: 3352-3357.
16. Caliskaner Z, Karaayvaz M, Ozturk S. Recurrent urticaria lesions in a heparin-allergic patient: most likely another form of "recall urticaria". J Investig Allergol Clin Immunol 2005; 15: 78-80.
17. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J 2006; 332: 325-329.
18. Cosgrove RH, Zacharski LR, Racine E, Andersen JC. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 2002; 28: 79-87.
19. Crafoord C. Preliminary report on postoperative treatment with heparin as a preventive of thrombosis. Acta Chir Scand 1937; 79: 407-426 .
20. Demir M, Iqbal O, Dietrich CP, Hoppensteadt DA, Ahmad S, Daud AN, Fareed J. Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I. Clin Appl Thromb Hemost 2001; 7: 44-52.
21. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hipfracture surgery. N Engl J Med 2001; 345: 1298-1304.
22. Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med 2007; 356: 1438-1444.
23. Greinacher A. Antigen generation in heparin-associated thrombocytopenia: the non-immunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost 1995; 21: 106-116.
24. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 886-892.
25. Grims RH, Weger W, Reiter H, Arbab E, Kranke B, Aberer W. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Br J Dermatol 2007; 157: 514-517.
26. Hach-Wunderle V, Kainer K, Krug B, Müller-Berghaus G, Pötzsch B. Heparin-associated thrombosis despite normal platelet counts. Lancet 1994; 344: 469-470.
27. Harenberg J, Huhle G, Wang L, Hoffmann U, Bayerl C, Kerowgan M. Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG. Allergy 1999; 54: 473-477.
28. Harr T, Scherer K, Tsakiris DA, Bircher AJ. Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux. Allergy 2006; 61: 787-788.
29. Hill J, Treasure T. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance. Br Med J 2007; 334: 1053-1054.
30. th ed). Chest 2008; 133: 71S-109S.
31. Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update. Blood Coagul Fibrinolysis 2006; 17: 605-613.
32. Jorpes E. The chemistry of heparin. Biochem J 1935; 29: 1817-1830.
33. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 10: 1948.
34. Kingery FA. Osteoporosis, fractures, and heparin therapy. JAMA 1965; 193: 152.
35. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-67.
36. Kneilling M, Rocken M. Mast cells: novel clinical perspectives from recent insights. Exp Dermatol 2009; 18: 488-496.
37. Komericki P, Grims RH, Kränke B, Aberer W. Acute generalized exanthematous pustolosis from dalteparin. J Am Acad Dermatol 2007; 57: 718-721.
38. Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-1720.
39. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994; 74: 38-45.
40. Li ZQ, Liu W, Park KS, Sachains BS, Arepally GM, Cines DB, Poncz M. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 2002; 99: 1230-1236.
41. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759-765.
42. Lopez S, Torres MJ, Rodriguez-Pena R, Blanca-Lopez N, Fernandez TD, Antunez C, Canto G, de L, V, Mayorga C. Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins. Br J Dermatol 2009; 160: 259-265.
43. Ludwig RJ, Alban S, Bislian R, Kaufmann R, Diehl S, Henschler R, Boehncke WH, Gille J. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on blood-borne metastasis in vivo. Thromb Haemost 2006; 95: 535-540.
44. Ludwig RJ, Alban S, Boehncke WH. Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. Mini Rev Med Chem 2006; 6: 1009-1023.
45. Ludwig RJ, Boehme B, Podda M, Tandi C, Jager E, Henschler R, Boehncke WH, Zollner TM, Kaufmann R, Gille J. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004; 64: 2743-2750.
46. Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thromb Haemost 2005; 94: 1265-1269.
47. Ludwig RJ, Schindewolf M, Lindhoff-Last E, Boehncke WH. The influence of heparin's molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157:514-17.
48. Br J Dermatol 2008; 158: 849-851.
49. Ludwig RJ, Schindewolf M, Utikal J, Lindhoff-Last E, Boehncke WH. Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb Haemost 2006; 96: 611-617.
50. Ludwig RJ, Schön MP, Boehncke WH. P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. Expert Opin Ther Targets 2007; 11: 1103-1117.
51. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106: 2710-2715.
52. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009; 374: 1149-1159.
53. Perrinaud A, Jacobi D, Machet MC, Grodet C, Gruel Y, Machet L. Bullous hemorrhagic dermatosis occurring at sites distant from subcutaneous injections of heparin: three cases. J Am Acad Dermatol 2006; 54: S5-S7.
54. Plancherel P. Klinische und gerinnungsphysiologische Untersuchungen mit einem neuem Heparindepotpräparat. Z Klin Med 1952; 150: 213-259.
55. Schindewolf M, Lindhoff-Last E. Fondaparinux-related thrombocytopenia in a patient with former HIT. Thromb Haemost 2008; 100: 168-169.
56. Schindewolf M, Ludwig RJ, Wolter M, Himsel A, Zgouras D, Kaufmann R, Boehncke WH, Lindhoff-Last E. Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin. J Eur Acad Dermatol Venereol 2008; 22: 378-380.
57. Schindewolf M, Schwaner S, Wolter M, Kroll H, Kaufmann R, Boehncke WH, Lindhoff-Last E, Ludwig RJ. Incidence and causes of heparin-induced skin lesions. CMAJ 2009; 181: 477-481.
58. Sculpher MJ, Lozano-Ortega G, Sambrook J, Palmer S, Ormanidhi O, Bakhai A, Flather M, Steg PG, Mehta SR, Weintraub W. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am Heart J 2009; 157: 845-852.
59. Singh S, Verma M, Bahekar A, Agrawal P, Duggal J, Ilescu M, Khosla P, Muzaffar S. Enoxaparin-induced skin necrosis: a fatal outcome. Am J Ther 2007; 14: 408-410.
60. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11: 7003-7011.
61. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood 1998; 91: 916-922.
62. Thuillier D, Chaby G, Dadban A, Dascotte E, Miquel-Christophe O, Andrejak M, Chatelain D, Lok C. Low-molecular-weight heparin-induced bullous haemorrhagic dermatosis associated with cell-mediated hypersensitivity. Ann Dermatol Venereol 2009; 136: 705-708.
63. Tiu A, Pang JM, Martin R, Officer N. Allergic reactions to enoxaparin and heparin: a case report and review of the literature. N Z Med J 2004; 117: U1126.
64. Uncu H. A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis. Phlebology 2009; 24: 56-60.
65. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88.
66. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92: 494-497.
67. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds). Heparin-induced thrombocytopenia. New York: Marcel Dekker 2004; 53-106.
68. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 311S-337S.
69. Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 2009; 8: 129-144.
70. th ed). Chest 2008; 133: 340S-380S.
71. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2655.
72. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005; 127: 1857-1861.
73. Weber HO, Fischer J, Kneilling M, Caroli U, Rocken M, Biedermann T. Recall urticaria induced by skin tests with heparin. Br J Dermatol 2009; 161: 187-189.